ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Pre-Tax Margin

Income before tax as a percentage of revenue.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin widens to 23.5%

Pre-tax margin was 23.5% in Q3 FY2026, up 7.5 pp from a year earlier. On a trailing-twelve-month basis it was 13.1%, down 13.1 pp year over year. Over 3 fiscal years it widened by 54.2 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
23.5%+8.4 pp QoQ
Last fiscal yearDec 2025
13.0%-14.0 pp YoY
LTMSep 2026
13.1%-13.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.5 pp——
1 year-14.0 pp——
3 years+54.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
13.0%
Year-over-year change
-14.0pp

Pre-Tax Margin vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Sep 2026 pre-tax margin of 13.1% is the highest of the 4 companies compared; the peer median is -68.7%.
  • Its year-over-year change of -13.1 pp is the 2nd highest of 3, against a peer median of -7.8 pp.
  • Over three fiscal years its change of +54.2 pp compares with a peer median of +138.3 pp.
ACAD Competitors Peer median
Pre-Tax Margin for ACAD and competitors
Company Period LTM level YoY 3-year change
ACADACADIA Pharmaceuticals Inc.LTM Sep 202613.1% -13.1 pp+54.2 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-24.6% +25.4 pp+345.2 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-68.7% -41.1 pp-68.6 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-536.4% ——
PRAXPraxis Precision Medicines, Inc.FY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ACAD) -68.7%-7.8 pp+138.3 pp

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.15M517.24M726.44M957.8M1.07B
Cost of Revenue19.14M10.17M45.73M81.84M89M
Gross Profit465M507.07M680.71M875.96M982.51M
Gross Margin96.0%98.0%93.7%91.5%91.7%
Research & Development239.42M361.58M351.62M303.25M328.8M
Selling, General & Admin396.03M369.09M402.47M488.43M548.89M
Operating Expenses635.44M730.67M754.09M645.16M877.7M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
EBITDA(164.18M)(211.42M)(45.48M)100.16M150.66M
EBITDA Margin-33.9%-40.9%-6.3%10.5%14.1%
Operating Income(170.44M)(223.6M)(73.38M)230.79M104.81M
Operating Margin-35.2%-43.2%-10.1%24.1%9.8%
Interest Income591K6.61M17.23M25.46M31.72M
Interest Expense00000
Other Income / Expenses2.92M10.15M22.34M27.28M34.09M
Income Before Tax(167.52M)(213.44M)(51.04M)258.08M138.9M
Pre-Tax Margin-34.6%-41.3%-7.0%26.9%13.0%
Income Tax Expense351K2.53M10.25M31.62M(252.1M)
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (Basic)(1.05)(1.34)(0.37)1.372.32
EPS (Diluted)(1.05)(1.34)(0.37)1.362.29
Weighted Avg Shares160.49M161.68M163.82M165.72M169.34M
Weighted Avg Shares (Diluted)160.49M161.68M163.82M166.36M171.36M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.